Skip to content

Chronic kidney disease — Overview

TL;DR — CKD is an abnormality of kidney structure or function lasting more than three months and carrying implications for health; prognosis is described by cause, GFR category and albuminuria category rather than by creatinine alone (KDIGO CKD Work Group 2024, PMID 38490803). The two-axis system matters because lower eGFR and higher albuminuria independently grade kidney-failure, cardiovascular and mortality risk (CKD Prognosis Consortium 2023, PMID 37787795). Global burden is large and rising, while awareness and urine-albumin testing remain weak links (GBD CKD Collaboration 2020, PMID 32061315). Disease-modifying therapy now spans RAS blockade, SGLT2 inhibition, finerenone in diabetic CKD and semaglutide in diabetic CKD, but their trial populations and indications are not interchangeable (Heerspink 2020, PMID 32970396).

What the condition owns

This condition owns persistent kidney dysfunction, its causes, progression, complications, kidney-directed treatment and the decision between replacement and conservative care. Glycaemic management belongs to the diabetes conditions; blood-pressure measurement and general drug choice belong to hypertension.

The dialysis and transplant corpora are deliberately compressed to the decision, timing and outcomes. Engineering of dialysis modalities, vascular-access technique and transplant immunosuppression protocols are outside scope.

The diagnostic object

CKD is not synonymous with a low single eGFR. Chronicity, urine albumin, urine sediment, imaging, histology, tubular disorders and transplant history can establish the diagnosis (KDIGO CKD Work Group 2024, PMID 38490803).

Albuminuria is both a marker of kidney damage and a risk axis. A person at G1 or G2 can have CKD through albuminuria or another marker; a person with G3a or lower has CKD when reduced GFR persists (Cirillo 2012, PMID 22038337).

Why the field changed

The 2021 CKD-EPI equations removed race and improved accuracy when creatinine and cystatin C were combined (Inker 2021, PMID 34554658). The change was paired with an explicit equity process, not merely a statistical refit (Delgado 2022, PMID 34563581).

DAPA-CKD and EMPA-KIDNEY established kidney protection in CKD with and without diabetes, while CREDENCE, FIDELIO-DKD and FLOW defined additional benefit in type 2 diabetes with CKD (Heerspink 2020, PMID 32970396) (EMPA-KIDNEY Collaborative Group 2023, PMID 36331190) (Perkovic 2019, PMID 30990260) (Bakris 2020, PMID 33264825) (Perkovic 2024, PMID 38785209).

The central implementation gap

Because early CKD is commonly asymptomatic, detection depends on blood and urine testing. Cost-effectiveness reviews find that targeted and population strategies depend strongly on risk threshold, treatment uptake and test costs (van Mil 2024, PMID 38213490) (Yeo 2024, PMID 38186904).

Condition map

Question Primary page Decision output
Does persistent abnormality meet CKD criteria? definition and measurement Cause–G–A classification
How common and how visible is it? epidemiology and burden Measured versus diagnosed burden
What caused it? causes and aetiology Cause-specific work-up and treatment
How fast might it progress? risk prediction Absolute kidney-failure risk and competing death
Which protective drug layer applies? RAS, SGLT2, MRA and GLP-1 pages Eligibility, benefit, harm and monitoring
Which failing-kidney complication dominates? Anaemia, CKD-MBD, cardiovascular and metabolic pages Outcome-specific management frame
Is a cause-specific therapy available? inherited and glomerular disease ADPKD, IgA and FSGS evidence
Is kidney replacement approaching? KRT decisions Timing, pathway and preparation
Would conservative care better fit goals? conservative care Survival–burden–quality trade-off
What does the patient experience reveal? symptom burden Fatigue, itch and life participation

The burden, restated on current numbers

GBD 2023 estimated 788 million (95% UI 743–843) adults aged 20 or over with CKD, an age-standardised adult prevalence of 14.2% (13.4–15.2), 1.48 million (1.30–1.65) deaths making CKD the ninth leading cause of death globally, and impaired kidney function accounting for 11.5% (8.4–14.5) of all cardiovascular deaths (GBD 2023 Chronic Kidney Disease Collaborators 2025, PMID 41213283). Age-standardised prevalence rose only 3.5% since 1990 while case counts more than doubled, so the growth is predominantly demographic. Stages G1–G3 constitute 13.9% of the 14.2% estimate.

Against that, lifetime risk of treated kidney failure is roughly 3.14% in men and 1.42% in women — about 1 in 32 and 1 in 71 — in a Japanese national registry estimate with competing-mortality adjustment (Wakasugi 2020, PMID 32040656). Against the 14.2% global adult prevalence estimate, those values are roughly fourfold and tenfold lower, respectively; the comparison is illustrative rather than direct because the populations and methods differ.

Five findings that changed what this condition is

  1. Risk is continuous, and both axes are independent. eGFR and albuminuria grade kidney, cardiovascular and mortality risk separately, so the KDIGO grid is a population summary of a continuous surface rather than a set of biological states (CKD Prognosis Consortium 2023, PMID 37787795). This is why the age-adaptation debate exists at all — every threshold on a continuum is administrative (Liu 2021, PMID 34459844).
  2. The kidney is now a treatable organ with a class effect. Pooling 13 placebo-controlled trials with 90,409 participants, SGLT2 inhibition reduced kidney disease progression by 37% (RR 0.63, 95% CI 0.58–0.69) with similar relative effects with and without diabetes and across primary kidney diagnoses (Nuffield Department of Population Health Renal Studies Group 2022, PMID 36351458), and the 2026 update shows the effect holds below a uACR of 200 mg/g (Staplin 2026, PMID 41202026).
  3. Most CKD prognosis is cardiovascular, and lipid-lowering stops working at the dialysis boundary. SHARP reduced major atherosclerotic events by 17% (RR 0.83, 0.74–0.94) in predominantly non-dialysis CKD (Baigent 2011, PMID 21663949) while AURORA found nothing on dialysis despite a 43% LDL reduction (Fellström 2009, PMID 19332456).
  4. Ancestry-informative biology exists but race does not encode it. APOL1 high-risk genotypes carry odds ratios near 10 for FSGS and 7 for hypertension-attributed ESKD, while African Americans without the genotype have non-diabetic CKD rates like European Americans (Genovese 2010, PMID 20647424) (Friedman 2011, PMID 21997396).
  5. Correcting the biochemistry of advanced CKD has largely failed. Cinacalcet (PMID 23121374), binder class (PMID 34003226), active vitamin D (PMID 22337679), erythropoiesis-stimulating agents to near-normal haemoglobin (PMID 19880844) and potassium normalisation on dialysis (PMID 40618849) all moved the number without moving the outcome.

Where the field is genuinely unresolved

These are not gaps to be filled by more of the same evidence; they are questions on which competent people currently disagree.

Question One side The other side
Should the eGFR threshold for CKD vary with age? Fixed criteria capture 54,342 people aged ≥65 with eGFR 45–59 and A1 whose kidney-failure risk is ≤0.12% and whose death risk exceeds it 69–935-fold (Liu 2021, PMID 34459844) Albuminuria already captures much of that risk, and any threshold on a continuous surface is administrative (CKD Prognosis Consortium 2023, PMID 37787795)
Does correcting metabolic acidosis slow CKD? Open-label bicarbonate halved creatinine doubling and mortality in 740 patients (Di Iorio 2019, PMID 31598912) A blinded acid-binder trial in 1,480 patients was null — but separated the arms by only ~1 mEq/L (Tangri 2024, PMID 38261535)
Is albuminuria a valid surrogate? Across 48 trials and 85,681 participants, each 30% uACR reduction predicted 19% lower kidney-failure hazard (Heerspink 2026, PMID 41198855) In FSGS, sparsentan produced sustained proteinuria remission and no eGFR slope difference at all (Rheault 2023, PMID 37921461)
Are steroidal and non-steroidal MRAs one class? Both act on the mineralocorticoid receptor Spironolactone was null in CKD (Hobbs 2024, PMID 39349629) and on dialysis (Walsh 2025, PMID 40818850), where finerenone works in diabetic CKD
Did race-free eGFR help or harm access? It unmasked a high-risk subgroup and reclassified 45.8% of Black adults with CKD upward (Muiru 2023, PMID 36069064) (Oliver 2024, PMID 39100866) It pushed 13–22% more Black patients below common trial-eligibility floors (Schmeusser 2023, PMID 36606692)

The gap that dominates everything else

The therapeutic layer is now large enough that the binding constraint is delivery, not efficacy. Fatigue affects roughly 70% (95% CI 60–79) of people with CKD before kidney replacement therapy (Fletcher 2022, PMID 35385471); the median global supply of nephrologists is 11.75 per million population, with Africa at 1.12 and South Asia at 1.81, and more than half of surveyed countries report nephrologist shortages (Okpechi 2024, PMID 39235198). A 37% relative reduction in progression is worth what the system can deliver of it.

Decision and interpretation matrix

Dimension Question Guardrail
Diagnostic axis Cause + G category + A category Avoid treating eGFR as the diagnosis
Time axis Chronicity and trajectory Separate acute change from persistent disease
Risk axis Kidney failure + cardiovascular events + death Show competing events
Treatment axis Eligibility, absolute benefit, harm, burden Do not rank drugs by relative effect alone
Measurement axis Assay, equation, repeatability State what was actually measured
Equity axis Testing, referral, access, affordability Audit downstream care, not labels only
Patient axis Symptoms, function, life participation Include outcomes patients prioritize
Evidence axis RCT, cohort, model, guideline Do not collapse designs

Evidence ledger

This ledger makes the page’s evidentiary mix inspectable. It does not imply that every source answers every question.

PMID Record used Role and boundary
38490803 KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. (KDIGO CKD Work Group 2024, PMID 38490803) Guideline or commentary; recommendation evidence depends on its review.
37787795 Estimated GFR, Albuminuria, and Adverse Outcomes: individual-participant data meta-analysis. (CKD Prognosis Consortium 2023, PMID 37787795) Synthesis; heterogeneity and included-study definitions constrain transport.
32061315 Global, regional, and national burden of chronic kidney disease, 1990-2017. (GBD CKD Collaboration 2020, PMID 32061315) Modelled projection; the estimate follows from the model inputs and assumptions, not from observed randomized follow-up.
32970396 Dapagliflozin in Patients with Chronic Kidney Disease. (Heerspink 2020, PMID 32970396) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
22038337 A population-based approach for the definition of chronic kidney disease: CKD Prognosis Consortium. (Cirillo 2012, PMID 22038337) Synthesis; heterogeneity and included-study definitions constrain transport.
34554658 New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. (Inker 2021, PMID 34554658) Observational or conceptual evidence; association is not treatment effect.
34563581 A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. (Delgado 2022, PMID 34563581) Guideline or commentary; recommendation evidence depends on its review.
36331190 Empagliflozin in Patients with Chronic Kidney Disease. (EMPA-KIDNEY Collaborative Group 2023, PMID 36331190) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
30990260 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. (Perkovic 2019, PMID 30990260) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
33264825 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. (Bakris 2020, PMID 33264825) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
38785209 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. (Perkovic 2024, PMID 38785209) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
38213490 Cost-effectiveness of screening for chronic kidney disease: evidence and gaps. (van Mil 2024, PMID 38213490) Guideline or commentary; recommendation evidence depends on its review.
38186904 Cost-effectiveness of screening for CKD in the general adult population: systematic review. (Yeo 2024, PMID 38186904) Synthesis; heterogeneity and included-study definitions constrain transport.
38519239 Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. (Levin 2024, PMID 38519239) Guideline or commentary; recommendation evidence depends on its review.
23243116 Cohort profile: the chronic kidney disease prognosis consortium. (Matsushita 2013, PMID 23243116) Observational or conceptual evidence; association is not treatment effect.
30348535 Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities. (Inker 2019, PMID 30348535) Synthesis; heterogeneity and included-study definitions constrain transport.
26757465 Multinational assessment of equations predicting kidney failure. (Tangri 2016, PMID 26757465) Synthesis; heterogeneity and included-study definitions constrain transport.
36857500 Kidney Failure Risk Equation evaluation with novel inputs in 59 cohorts. (Grams 2023, PMID 36857500) Observational or conceptual evidence; association is not treatment effect.
26028594 eGFR and albuminuria for prediction of cardiovascular outcomes: individual-participant meta-analysis. (Matsushita 2015, PMID 26028594) Synthesis; heterogeneity and included-study definitions constrain transport.
41205219 Chronic Kidney Disease Prevalence and Awareness Among US Adults. (Gong 2026, PMID 41205219) Observational or conceptual evidence; association is not treatment effect.
39137037 Screening for chronic kidney disease: change of perspective and novel developments. (van Mil 2024, PMID 39137037) Observational or conceptual evidence; association is not treatment effect.
40227684 Balancing Efficiency and Equity in Population-Wide CKD Screening. (Cusick 2025, PMID 40227684) Modelled projection; the estimate follows from the model inputs and assumptions, not from observed randomized follow-up.
37403003 Chronic kidney disease of unknown aetiology: a global review. (Rao 2023, PMID 37403003) Observational or conceptual evidence; association is not treatment effect.
33116757 Mesoamerican Nephropathy: What We Know so Far. (Sanchez Polo 2020, PMID 33116757) Observational or conceptual evidence; association is not treatment effect.
18161745 Cellular and molecular mechanisms of fibrosis. (Wynn 2008, PMID 18161745) Observational or conceptual evidence; association is not treatment effect.
7246778 Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. (Hostetter 1981, PMID 7246778) Observational or conceptual evidence; association is not treatment effect.
24522492 Relative risks of CKD for mortality and end-stage renal disease across races are similar. (Wen 2014, PMID 24522492) Observational or conceptual evidence; association is not treatment effect.
37952217 Estimated lifetime benefits of combination SGLT2, GLP-1 and non-steroidal MRA therapy. (Neuen 2024, PMID 37952217) Modelled projection; the estimate follows from the model inputs and assumptions, not from observed randomized follow-up.
40470996 Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (CONFIDENCE). (Agarwal 2025, PMID 40470996) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.

What can and cannot be concluded

  • Risk associations do not by themselves establish that changing the marker changes risk.
  • A relative effect must be paired with baseline risk, follow-up and the exact endpoint.
  • Albuminuria, acute eGFR change, chronic eGFR slope and kidney failure are not interchangeable.
  • Subgroup consistency is not evidence that every subgroup had adequate power.
  • Guideline recommendations combine evidence with values, feasibility, cost and service capacity.
  • Older adults require competing-mortality and treatment-burden framing.
  • Dialysis and transplantation comparisons are vulnerable to eligibility and immortal-time bias.
  • Modelled lifetime benefit is not a randomized observed benefit.
  • A biochemical response without a patient-important outcome remains a surrogate result.
  • This page is research synthesis, not individualized medical advice.

Research-design checklist

  • Define CKD cause, G category, A category and chronicity at baseline.
  • Report the creatinine or cystatin C equation and laboratory calibration.
  • Prespecify acute and chronic eGFR slopes when haemodynamic effects are expected.
  • Keep sustained GFR decline, kidney failure and replacement therapy separable.
  • Report absolute event risks, follow-up and confidence intervals with relative effects.
  • Treat death as a competing event where it can preclude kidney failure.
  • Measure hyperkalaemia, acute kidney injury and treatment discontinuation consistently.
  • Include symptoms, function, life participation and treatment burden.
  • Describe background RAS, SGLT2, MRA and GLP-1 therapy explicitly.
  • Prespecify albuminuria and cause strata without over-reading underpowered interactions.
  • Record screening, prescribing, persistence and monitoring as separate implementation steps.
  • Report representation, access and affordability variables needed for equity analysis.

Open questions

  • Does adding cystatin C to routine creatinine reporting change referral, drug eligibility and transplant access, or only the number on the report? The equation work established accuracy; the downstream care question is untested (Inker 2021, PMID 34554658) (Delgado 2022, PMID 34563581). → OQ-5
  • Which step of the conversion chain — testing, recognition, communication, prescribing, monitoring, persistence — loses the most of the trial-demonstrated benefit? Screening economics turn on treatment delivery, but no study apportions the loss across steps (van Mil 2024, PMID 38213490) (Yeo 2024, PMID 38186904). → OQ-4
  • What is the absolute, not relative, benefit of each drug layer once competing death is modelled explicitly at each G–A cell? Relative effects are consistent across strata; absolute benefit is not.

  • Do the four disease-modifying classes combine additively on kidney failure? Only the finerenone–empagliflozin pair has been randomized, and only on 180-day albuminuria (Agarwal 2025, PMID 40470996); the four-class estimate is modelled (Neuen 2024, PMID 37952217). → OQ-1

  • Given that lifetime risk of treated kidney failure is about 1 in 32 men and 1 in 71 women (Wakasugi 2020, PMID 32040656) against a 14.2% adult prevalence (GBD 2023 CKD Collaborators 2025, PMID 41213283), what does a CKD diagnosis actually predict for the average person who receives one?

  • Why has almost every attempt to correct the biochemistry of advanced CKD failed while every attempt to modify glomerular haemodynamics has succeeded — and does that generalise to targets not yet tested?
  • Is the binding constraint on CKD outcomes now efficacy or delivery, given a 37% relative reduction in progression (PMID 36351458) against a median global supply of 11.75 nephrologists per million (PMID 39235198)?

References

  1. KDIGO CKD Work Group et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. PMID 38490803
  2. CKD Prognosis Consortium et al. Estimated GFR, Albuminuria, and Adverse Outcomes: individual-participant data meta-analysis. JAMA. 2023;330(13):1266-1277. PMID 37787795
  3. GBD CKD Collaboration et al. Global, regional, and national burden of chronic kidney disease, 1990-2017. Lancet. 2020;395(10225):709-733. PMID 32061315
  4. Heerspink et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. PMID 32970396
  5. Cirillo et al. A population-based approach for the definition of chronic kidney disease: CKD Prognosis Consortium. J Nephrol. 2012;25(1):7-12. PMID 22038337
  6. Inker et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. PMID 34554658
  7. Delgado et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022;79(2):268-288.e1. PMID 34563581
  8. EMPA-KIDNEY Collaborative Group et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127. PMID 36331190
  9. Perkovic et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. PMID 30990260
  10. Bakris et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. PMID 33264825
  11. Perkovic et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. PMID 38785209
  12. van Mil et al. Cost-effectiveness of screening for chronic kidney disease: evidence and gaps. Clin Kidney J. 2024;17(1):sfad254. PMID 38213490
  13. Yeo et al. Cost-effectiveness of screening for CKD in the general adult population: systematic review. Clin Kidney J. 2024;17(1):sfad137. PMID 38186904
  14. Levin et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. PMID 38519239
  15. Matsushita et al. Cohort profile: the chronic kidney disease prognosis consortium. Int J Epidemiol. 2013;42(6):1660-1668. PMID 23243116
  16. Inker et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities. Am J Kidney Dis. 2019;73(2):206-217. PMID 30348535
  17. Tangri et al. Multinational assessment of equations predicting kidney failure. JAMA. 2016;315(2):164-174. PMID 26757465
  18. Grams et al. Kidney Failure Risk Equation evaluation with novel inputs in 59 cohorts. J Am Soc Nephrol. 2023;34(3):482-494. PMID 36857500
  19. Matsushita et al. eGFR and albuminuria for prediction of cardiovascular outcomes: individual-participant meta-analysis. Lancet Diabetes Endocrinol. 2015;3(7):514-525. PMID 26028594
  20. Gong et al. Chronic Kidney Disease Prevalence and Awareness Among US Adults. JAMA Cardiol. 2026;11(1):77-81. PMID 41205219
  21. van Mil et al. Screening for chronic kidney disease: change of perspective and novel developments. Curr Opin Nephrol Hypertens. 2024;33(6):583-592. PMID 39137037
  22. Cusick et al. Balancing Efficiency and Equity in Population-Wide CKD Screening. JAMA Netw Open. 2025;8(4):e254740. PMID 40227684
  23. Rao et al. Chronic kidney disease of unknown aetiology: a global review. Trop Med Int Health. 2023;28(8):588-600. PMID 37403003
  24. Sanchez Polo et al. Mesoamerican Nephropathy: What We Know so Far. Int J Nephrol Renovasc Dis. 2020;13:261-272. PMID 33116757
  25. Wynn et al. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210. PMID 18161745
  26. Hostetter et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241(1):F85-F93. PMID 7246778
  27. Wen et al. Relative risks of CKD for mortality and end-stage renal disease across races are similar. Kidney Int. 2014;86(4):819-827. PMID 24522492
  28. Neuen BL, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450-462. PMID 37952217
  29. Agarwal R, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543. PMID 40470996
  30. GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10518):2461-2482. PMID 41213283
  31. Wakasugi M, et al. Lifetime and age-conditional risk estimates of end-stage kidney disease requiring maintenance dialysis in Japan. Clin Exp Nephrol. 2020;24(6):518-525. PMID 32040656
  32. Liu P, et al. Accounting for Age in the Definition of Chronic Kidney Disease. JAMA Intern Med. 2021;181(10):1359-1366. PMID 34459844
  33. Nuffield Department of Population Health Renal Studies Group. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-1801. PMID 36351458
  34. Staplin N, et al. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis. JAMA. 2026;335(3):220-232. PMID 41202026
  35. Baigent C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192. PMID 21663949
  36. Fellstrom BC, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407. PMID 19332456
  37. Genovese G, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-845. PMID 20647424
  38. Friedman DJ, et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011;22(11):2098-2105. PMID 21997396
  39. Chertow GM, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-2494. PMID 23121374
  40. Ogata H, et al. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA. 2021;325(19):1946-1954. PMID 34003226
  41. Thadhani R, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674-684. PMID 22337679
  42. Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032. PMID 19880844
  43. Fishbane S, et al. The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney Int. 2025;108(4):686-694. PMID 40618849
  44. Di Iorio BR, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019;32(6):989-1001. PMID 31598912
  45. Tangri N, et al. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis. J Am Soc Nephrol. 2024;35(3):311-320. PMID 38261535
  46. Heerspink HJL, et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med. 2026;32(1):281-287. PMID 41198855
  47. Rheault MN, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023;389(26):2436-2445. PMID 37921461
  48. Hobbs FDR, et al. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat Med. 2024;30(12):3634-3645. PMID 39349629
  49. Walsh M, et al. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet. 2025;406(10504):695-704. PMID 40818850
  50. Muiru AN, et al. Effect of Adopting the New Race-Free 2021 CKD-EPI eGFR Creatinine Equation on Racial Differences in Kidney Disease Progression Among People With HIV: An Observational Study. Clin Infect Dis. 2023;76(3):461-468. PMID 36069064
  51. Oliver JD, et al. Impact of Race-Free Glomerular Filtration Rate Estimations on CKD Prevalence in the US Military Health System: A Retrospective Cohort Study. Kidney Med. 2024;6(8):100861. PMID 39100866
  52. Schmeusser BN, et al. Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment. Cancer. 2023;129(6):920-924. PMID 36606692
  53. Fletcher BR, et al. Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLoS Med. 2022;19(4):e1003954. PMID 35385471
  54. Okpechi IG, et al. A global assessment of kidney care workforce. Nephrol Dial Transplant. 2024;39(Supplement_2):ii43-ii48. PMID 39235198